0001810560false00018105602026-11-132026-11-130001810560us-gaap:CommonStockMember2026-11-132026-11-130001810560revb:SeriesBJuniorParticipatingPreferredPurchaseRightsMember2026-11-132026-11-130001810560revb:RedeemableWarrantsEachExercisableForA1201600ThShareOfCommonStockAtAnExercisePriceOf2318400PerShareMember2026-11-132026-11-13
`
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): November 13, 2026 |
REVELATION BIOSCIENCES, INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware |
001-39603 |
84-3898466 |
(State or Other Jurisdiction
of Incorporation) |
(Commission File Number) |
(IRS Employer
Identification No.) |
|
|
|
|
|
4660 La Jolla Village Drive Suite 100 |
|
San Diego, California |
|
92122 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: (650) 800-3717 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s) |
|
Name of each exchange on which registered
|
Common stock, par value $0.001 per share |
|
REVB |
|
The Nasdaq Stock Market LLC |
Redeemable warrants, each exercisable for a 1/1,411,200th share of common stock at an exercise price of $16,228,800.00 per share |
|
REVBW |
|
The Nasdaq Stock Market LLC |
Series B junior participating preferred purchase rights |
|
N/A |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
Disclosure Channels
Revelation Biosciences, Inc. (the “Company”) wishes to notify the investment community and others that in the future, we may choose to communicate material information about us and our services and for complying with our disclosure obligation under Regulation FD via social media channels.
The Company has identified its social media channels for material information as follows:
|
|
X (f/k/a Twitter): |
x.com/RevelationBio_ |
Facebook: |
facebook.com/RevelationBiosciences |
Instagram: |
instagram.com/RevelationBiosciences |
Threads: |
threads.com/@revelationbiosciences |
LinkedIn: |
linkedin.com/company/revelation-biosciences-inc |
TikTok: |
tiktok.com/@revelation.bioscie |
YouTube: |
youtube.com/@RevelationBiosciences |
Discord: |
discord.com/users/1569838501355069483 |
Reddit: |
reddit.com/user/RevelationBio |
The Company will also use its landing page on its corporate website (www.revbiosciences.com) to host social media disclosures and/or links to/from such disclosures. The information we post through these social media channels may be deemed material. Accordingly, investors should monitor these social media channels in addition to following our website, press releases, SEC filings and public conference calls and webcasts. The social media channels that we intend to use as a means of disclosing the information described above may be updated from time to time as listed on our website.
Neither the information in this Item 7.01 or any social media post are to be deemed to be “furnished” and shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
Social media posts may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. See our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q for a list of such factors which may have an influence on our forward-looking statements.
The information set forth in this Item 7.01 shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
|
|
|
|
Exhibit No. |
|
Description |
104 |
|
Cover Page Interactive Data File (embedded with the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
REVELATION BIOSCIENCES, INC. |
|
|
|
Date: November 13, 2026 |
By: |
/s/ Chester S. Zygmont, III |
|
|
Chester S. Zygmont, III
Chief Financial Officer
(principal financial and accounting officer) |
